Irinotecan for Advanced and Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This trial aims to evaluate the safety and efficacy of third-line or later irinotecan
treatment for locally recurrent or metastatic breast cancer among Chinese patients who have
received at least two regimens containing anthracyclines and taxanes.